Record mula sa primary source
Decision-gradePag-apruba ng FDA
Denali Therapeutics Inc. · Inaprubahan ng FDA ang Avlayah (tividenofusp alfa-eknm)
Inilista ng FDA ang Avlayah (tividenofusp alfa-eknm) bilang bagong pag-apruba ng gamot #8 ng 2026 noong 2026-03-24: Upang gamutin ang ilang indibidwal na may Hunter syndrome (Mucopolysaccharidosis type II o MPS II)
Mahahalagang fact
- Na-file
- Mar 24, 2026, 12:00 AM
- Kaganapan
- Pag-apruba ng FDA
- Direksyon
- Positibo
- Kumpanya
DNLIDenali Therapeutics- Asset
- tividenofusp alfa
- Pinagmulan
- FDA Novel Drug Approvals
- Kumpiyansa
- May source
Higit pa tungkol sa asset na ito
Minor
Hun 18, 2026
12:00 PM
DNLIDenali TherapeuticsDenali nagbebenta ng Rare Pediatric Disease PRV sa halagang $195 million
Decision-grade
May 7, 2026
08:03 PM
DNLIDenali TherapeuticsDecision-grade
Peb 26, 2026
09:07 PM
DNLIDenali TherapeuticsDecision-grade
Ene 6, 2026
01:02 PM
DNLIDenali TherapeuticsKapansin-pansin
Dis 4, 2025
12:01 PM
DNLIDenali TherapeuticsDenali Therapeutics 2025 Investor Day – timeline ng paglulunsad ng ETV franchise
Materyal
Dis 4, 2025
12:01 PM
DNLIDenali TherapeuticsDecision-grade
Nob 6, 2025
09:03 PM
DNLIDenali TherapeuticsDecision-grade
Okt 14, 2025
12:10 PM
DNLIDenali Therapeutics